%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
101 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T10:36:56Z
2024-03-28T22:06:22-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T22:06:22-07:00
application/pdf
Heather
201018.nov
uuid:6fb0aca8-1dd2-11b2-0a00-140a277d8900
uuid:6fb0acab-1dd2-11b2-0a00-d30000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
21 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2001; 28:1)74 (1)]TJ
0 Tw -45.8691 -0.0313 Td
(2448)Tj
ET
0 0 0 0 scn
/GS0 gs
105.49 58.25 407.5 -10.83 re
f*
0.5 w
105.49 58.25 407.5 -10.83 re
S
BT
0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(4.)-875 (Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. )17.8 (The)]TJ
1.675 -1.25 Td
(ACR nomenclature and case definitions for neuropsychiatric lupus)Tj
0 -1.25 TD
[(syndromes. )54.9 (Arthritis Rheum 1999;42:599-608.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Moran MG, Dubester SN, Stoudemire )54.8 (A, Fogel BS, editors.)]TJ
0 Tc 1.675 -1.25 Td
(Psychiatric care of the medical patient. Connective tissue diseases.)Tj
-0.00011 Tc T*
[(New )36.8 (Y)100 (ork: Oxford University Press; 1993:739-56.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (W)79.7 (ekking EM, )17.7 (V)60 (ingerhoets )54.8 (AJJM, van Dam )54.8 (AP)110.7 (. Daily stressors and)]TJ
0 Tc 1.675 -1.25 Td
[(systemic lupus erythematosus: )54.8 (A)-219.8 (longitudinal analysis. First)]TJ
-0.00011 Tc T*
(findings. Psychother Psychosom 1991;4:503-8.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Adams SGJ, Dammers PM, Saia )17.7 (TL, Brantley PJ, Gaydos GR.)]TJ
0 Tc 1.675 -1.25 Td
(Stress, depression, and anxiety predict average symptom severity)Tj
T*
(and daily symptom fluctuation in systemic lupus erythematosus. )Tj
T*
(J Behav Med 1994;17:459-77.)Tj
-1.675 -1.25 Td
[(8.)-875 (McCracken LM, Semenchuk EM, Goetsch )17.7 (VL. Cross-sectional and)]TJ
1.675 -1.25 Td
(longitudinal analyses of coping responses and health status in)Tj
-0.00011 Tc T*
(persons with systemic lupus erythematosus. J Behav Med)Tj
0 Tc 0 Tw T*
(1995;20:179-87.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Menon S, Jameson-Shortall E, Newman SP)110.7 (, Hall-Craggs MR,)]TJ
0 Tc 1.675 -1.25 Td
[(Chinn R, Isenber)17.8 (g DA. )54.8 (A)-219.8 (longitudinal study of anticardiolipin)]TJ
T*
(antibody levels and cognitive functioning in systemic lupus)Tj
T*
[(erythematosus. )54.9 (Arthritis Rheum 1999;42:735-41.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Hanly JG, Hong C, Smith S, Fisk JD. )54.8 (A)-219.9 (prospective analysis of)]TJ
0 Tc 2.175 -1.25 Td
(cognitive function and anticardiolipin antibodies in systemic lupus)Tj
T*
[(erythematosus. )54.9 (Arthritis Rheum 1999;42:728-34.)]TJ
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (W)79.7 (est SG, Emlen )17.7 (W)91.7 (,)-0.1 ( )17.7 (W)79.7 (ener MH, Kotzin BL. Neuropsychiatric lupus)]TJ
0 Tc 2.1381 -1.25 Td
(erythematosus: a 10-year prospective study on the value of)Tj
T*
[(diagnostic tests. )54.9 (Am J Med 1995;99:153-63.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Dobkin PL, Da Costa D, Dritsa M, et al. Quality of life in SLE)]TJ
0 Tc 2.175 -1.25 Td
[(patients during more and less active disease states: dif)17.8 (ferential)]TJ
T*
[(contributors to mental and physical health. )54.8 (Arthritis Care Res)]TJ
0 Tw T*
(1999;12:401-10.)Tj
0.0249 Tw -2.175 -1.25 Td
[(13.)-875 (T)69.8 (an EM, Cohen )54.8 (AS, Fries JF)79.8 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
0.02499 Tw -2.175 -1.25 Td
[(14.)-875 (Dobkin PL, Clarke )54.9 (A, Da Costa D, et al. Counterbalancing patient)]TJ
2.175 -1.25 Td
(demands with evidence: results from a pan-Canadian randomized)Tj
-0.00011 Tc T*
(clinical trial of brief supportive-expressive group psychotherapy for)Tj
0 Tc T*
[(women with systemic lupus erythematosus. )54.9 (Ann Behav Med 2002;)]TJ
-0.00011 Tc T*
(\(in press\).)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Derogatis LR. SCL-90-R. )54.8 (Administration, scoring and procedures)]TJ
0 Tc 2.175 -1.25 Td
(manual. 3rd ed. Minneapolis: National Computer Systems; 1994.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Sarason IG, Sarason BR, Shearin EN, Pierce GR. )54.8 (A)-219.9 (brief measure)]TJ
0 Tc 2.175 -1.25 Td
(of social support: Practical and theoretical implications. J Soc Pers)Tj
T*
(Relationships 1987;4:497-510.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(17.)-875.1 (Endler NS, Parker JD. Coping inventory for stressful situations)]TJ
0 Tc 2.175 -1.25 Td
[(manual. )17.8 (T)69.8 (oronto: Multi-Health Systems Inc.; 1990.)]TJ
-2.175 -1.25 Td
[(18.)-875 (Smith CA, )17.7 (W)79.8 (allston KA. )54.8 (Adaptation in patients with chronic)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis: )54.9 (Application of a general model. Health)]TJ
T*
[(Psychol 1992;1)36.9 (1:151-62.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Thompson RJ, Gil KM, )54.8 (Abrams MR, Philips G. Stress, coping and)]TJ
0 Tc 2.175 -1.25 Td
(psychological adjustment of adults with sickle cell disease. )Tj
T*
(J Consult Clin Psychol 1992;60:433-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (DeLongis )54.8 (A, Folkman S, Lazarus RS. )17.7 (The impact of daily stress on)]TJ
0 Tc 2.175 -1.25 Td
(health and mood: psychological and social resources as mediators. )Tj
-0.00011 Tc T*
(J Pers Soc Psychol 1988;54:486-95.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (W)79.7 (are JE, Sherbourne CD. )17.7 (The MOS 36-item Short-Form Health)]TJ
2.175 -1.25 Td
(Survey \(SF-36\). I. Conceptual framework and item selection. Med)Tj
0 Tc T*
(Care 1992;30:473-83.)Tj
-0.00011 Tc 30.825 71.25 Td
[(22.)-875.1 (Brazier JE, Haprer R, Jones NMB, O\222Cathain )54.8 (A, Usherwood )17.7 (T)73.9 (,)]TJ
0 Tc 2.175 -1.25 Td
[(W)79.8 (estlake L. )17.8 (V)111.1 (alidating the SF-36 health survey questionnaire: new)]TJ
T*
(outcome measure for primary care. BMJ 1992;305:160-4.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (W)79.7 (are JE, Kosinski M, Bayliss MS, McHorney CA, Rogers )17.7 (WH,)]TJ
0 Tc 2.175 -1.25 Td
[(Raczek )54.8 (A. Comparison of methods for the scoring and statistical)]TJ
-0.00011 Tc T*
(analysis of SF-36 health profile and summary measures: summary)Tj
T*
[(of results from the Medical Outcomes Study)64.8 (. Med Care 1995;33)]TJ
0 Tc 0 Tw T*
(Suppl:64-79.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (W)79.7 (are JE, Kosinski M, Keller SD. SF-36 Physical and mental health)]TJ
0 Tc 2.175 -1.25 Td
[(summary scales: )54.8 (A)-219.8 (user)-36.9 (\222)55.2 (s manual. 4th ed. Boston: )17.7 (The Health)]TJ
T*
(Institute; 1994.)Tj
0.0072 Tw -2.175 -1.25 Td
[(25.)-875 (Hopman WM, T)69.8 (owheed T)74 (, )37.1 (Anastassiades T)74 (, )-17.8 (et )-17.8 (al. )-17.8 (Canadian)]TJ
0.0249 Tw 2.175 -1.25 Td
[(normative data for the SF-36 health survey)64.9 (. Can Med )54.8 (Assoc J)]TJ
0 Tw T*
(2000;163:265-71.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Bruce IN, Mak )17.7 (VC, Hallett DC, Urowitz MB. Factors associated)]TJ
0 Tc 2.175 -1.25 Td
[(with fatigue in patients with systemic lupus erythematosus. )54.9 (Ann)]TJ
T*
(Rheum Dis 1999;58:379-81.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875.1 (Liang MH, Socher SA, Larson MG, Schur PH. Reliability and)]TJ
2.175 -1.25 Td
(validity of six systems for the clinical assessment of disease)Tj
0 Tc T*
[(activity in SLE. )54.9 (Arthritis Rheum 1989;32:1)36.8 (107-18.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875.1 (Abrahamowicz M, Fortin PR, du Ber)17.7 (ger R, Nayak )17.7 (V)129.1 (,)-0.1 ( Neville C,)]TJ
0 Tc 2.175 -1.25 Td
[(Liang MH. )17.7 (The relationship between disease activity and expert)]TJ
T*
[(physician\222)54.9 (s decision to start major treatment in active systemic)]TJ
T*
[(lupus erythematosus: )54.9 (A)-219.8 (decision aid for development of entry)]TJ
T*
(criteria for clinical trials. J Rheumatol 1998;25:277-84.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(29.)-875.1 (Bombardier CH, Gladman DD, Urowitz MB, Caron D, Chang CH.)]TJ
0 Tc 2.175 -1.25 Td
[(Derivation of the SLEDAI. )54.8 (A)-219.8 (disease activity index for lupus)]TJ
T*
[(patients. )17.8 (The Committee on Prognosis Studies in SLE. )54.9 (Arthritis)]TJ
T*
(Rheum 1992;35:630-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875.1 (Fortin P)110.7 (,)-0.1 ( )54.8 (Abrahamowicz M, Clarke )54.8 (AE, et al. Do lupus disease)]TJ
0 Tc 2.175 -1.25 Td
(activity measures detect clinically important change? J Rheumatol)Tj
0 Tw T*
(2000;27:1421-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Gladman D, Ginzler E, Goldsmith C, Fortin P)110.7 (, Liang MH, Urowitz)]TJ
0 Tc 2.175 -1.25 Td
[(MB. )17.8 (The development and initial validation of the SLICC/ACR)]TJ
T*
[(damage index for SLE. )54.9 (Arthritis Rheum 1996;39:363-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(32.)-875.1 (Gladman D, Urowitz MB, Goldsmith C, Fortin P)110.7 (,)-0.1 ( Ginzler E,)]TJ
0 Tc 2.175 -1.25 Td
[(Gordon C. )17.7 (The reliability of the SLICC/ACR damage index in)]TJ
T*
[(patients with SLE. )54.9 (Arthritis Rheum 1997;40:809-13.)]TJ
-2.175 -1.25 Td
[(33.)-875 (Cohen J, Cohen P)110.8 (. )54.8 (Applied multiple regression: Correlation analysis)]TJ
2.175 -1.25 Td
(for the behavioral sciences. Hillsdale: Erlbaum; 1983.)Tj
-2.175 -1.25 Td
[(34.)-875 (Giang DW)91.8 (. Systemic lupus erythematosus and depression.)]TJ
2.175 -1.25 Td
(Neuropsychiatry Neuropsychol Behav Neurol 1991;4:78-82.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Utset )17.7 (T)17.7 (O, Golden M, Siberry G, Kiri N, Crum RM, Petri MA.)]TJ
2.175 -1.25 Td
(Depressive symptoms in patients with systemic lupus)Tj
0 Tc T*
(erythematosus: association with central nervous system lupus and)Tj
T*
[(Sjogren\222)54.9 (s syndrome. J Rheumatol 1994;21:2039-45.)]TJ
-2.175 -1.25 Td
[(36.)-875 (Peterson L. Special series: Coping with medical illness and medical)]TJ
2.175 -1.25 Td
(procedures. J Consult Clin Psychol 1989;57:331-2.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(37.)-875.1 (McKinley PS, Ouellette SC, )17.7 (W)39.7 (inkel GH. )17.7 (The contributions of)]TJ
0 Tc 2.175 -1.25 Td
[(disease activity)64.9 (, sleep patterns, and depression to fatigue in)]TJ
T*
[(systemic lupus erythematosus. )54.8 (A)-219.8 (proposed model. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1995;38:826-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (Fifield J, McQuillan J, )17.7 (T)69.7 (ennen H, et al. History of af)17.7 (fective disorder)]TJ
0 Tc 2.175 -1.25 Td
[(and the temporal trajectory of fatigue in rheumatoid arthritis. )54.9 (Ann)]TJ
T*
(Behav Med 2001;23:34-41.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(39.)-875.1 (Denbur)17.7 (g SD, Carbotte RM, Denbur)17.7 (g JA. Psychological aspects of)]TJ
0 Tc 2.175 -1.25 Td
(systemic lupus erythematosus: cognitive function, mood, and self-)Tj
T*
(report. J Rheumatol 1997;24:998-1003.)Tj
-2.175 -1.25 Td
[(40.)-875 (T)69.8 (aylor SE. Health psychology)64.9 (. New )36.8 (Y)100.1 (ork: McGraw-Hill; 1991.)]TJ
ET
1 w
55 54 m
559 54 l
S
0 0 0 0 scn
/GS0 gs
105.49 58.25 407.5 -10.83 re
f*
0.5 w
105.49 58.25 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
86 0 obj
<>
endobj
106 0 obj
<>
endobj
47 0 obj
<>
endobj
55 0 obj
<>
endobj
54 0 obj
<>
endobj
74 0 obj
<>stream
HtV
pT}ow BB$nPAHJ6a7@#Jq$D?PabˏZpD$)V`dlS:@[vPR/s=ܳo@er .MuRe$Twax`qrq痉W7?QZ:˵k'puj%\{6=#4t;W+HC]ŋ{2D~G{$<T?3GEE̛Ϣj<prC:JFh[.b@E?sw@G2r.Q$#D!E<8-1M
@Ί&CyN fa-^vmd5ܷ՜)zj,m 6l.JU˸.YzXXwȮP9sd+>IE%FNM,z.$f~ʘ"f767;,-ӧ8[+f oā/gw#1wu H̡E_HȞr}jMZ}~Qhlͷ6Y'oX(R.)
TO*.ػy|HgD-_ZJ$3x (w)١jiZ6Lmvho8pR2Z]}.z*Xvfe6NcyXfI9H3C8SřNy"_2ϱ/&RQ&~fr5A6vu!qRgI5!]2ErR,RHVʰ\ #r=
,[dP+B$Sk:E[=Uחse_W$PLg3Ϲعym9gaM>X*7cc97 g$i f0~d0_Jr>3)1Gn8ӡkR`H( źASht#DCCT}鎙0*7c,B2aJy^-
}(g5WP@?ܫz
^zվlEY~Cv/NĎc_qb·M ,´@
cPJHZQajR8uCRM[mQ2-e?=swιw|6ԇh\YE'xg2j`O1NkSv碰UWPRԥ
@5TA-'o /4kQQQŨ15FcT_ UVBP)|II}=UjE^:ǒ`Go|لVt@U<߇x$c
H6B:v"'>t͂6Cskf
H8,0peq+9q9ːprqܴNAI:3"u~L A3%-E3X
!C!Fπw;g0ˑۜu&tgY)}Όo4yoL'~juz:Sx]